BIOHAVEN JPM 2025JAN12 FINAL.pdf

1、 2025 Biohaven,Ltd.All rights reserved.43rd Annual J.P.Morgan Healthcare ConferenceJanuary 13,2025Vlad Coric,M.D.Chairman and Chief Executive OfficerJENNIFER Living with SCA3Participant in the Troriluzole Clinical Study Forward-Looking StatementThis presentation includes forward-looking statements w

2、ithin the meaning of the Private Securities Litigation Reform Act of 1995,including statements about Biohaven Ltd.(the“Company”)and our planned and ongoing clinical trials for our taldefgrobep alfa,troriluzole,BHV-2100,BHV-7000,BHV-8000,BHV-1300,BHV-1310,BHV-1510 and BHV-1530 development programs,th

3、e timing of and the availability of data from our clinical trials,the timing and our decisions to proceed with our planned regulatory filings,the timing of and our ability to obtain regulatory approvals for our product candidates,the clinical potential utility of our product candidates,alone and as

4、compared to other existing potential treatment options,and the potential advancement of our early phase programs including BHV-1400,BHV-1500,and BHV-1600.The use of certain words,including“continue”,“plan”,“will”,“believe”,“may”,“expect”,“anticipate”and similar expressions,is intended to identify fo

5、rward-looking statements.Investors are cautioned that any forward-looking statements,including statements regarding the future development,timing and potential marketing approval and commercialization of our development candidates,are not guarantees of future performance or results and involve subst

6、antial risks and uncertainties.Actual results,developments and events may differ materially from those in the forward-looking statements as a result of various factors including:the expected timing,commencement and outcomes of Biohavens planned and ongoing clinical trials;the timing of planned inter